JP2022549328A5 - - Google Patents

Info

Publication number
JP2022549328A5
JP2022549328A5 JP2022518957A JP2022518957A JP2022549328A5 JP 2022549328 A5 JP2022549328 A5 JP 2022549328A5 JP 2022518957 A JP2022518957 A JP 2022518957A JP 2022518957 A JP2022518957 A JP 2022518957A JP 2022549328 A5 JP2022549328 A5 JP 2022549328A5
Authority
JP
Japan
Prior art keywords
composition according
approximately
concentration
composition
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022518957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549328A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/052935 external-priority patent/WO2021062317A1/en
Publication of JP2022549328A publication Critical patent/JP2022549328A/ja
Publication of JP2022549328A5 publication Critical patent/JP2022549328A5/ja
Pending legal-status Critical Current

Links

JP2022518957A 2019-09-25 2020-09-25 細胞外小胞組成物 Pending JP2022549328A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962906018P 2019-09-25 2019-09-25
US62/906,018 2019-09-25
US201962906485P 2019-09-26 2019-09-26
US62/906,485 2019-09-26
PCT/US2020/052935 WO2021062317A1 (en) 2019-09-25 2020-09-25 Extracellular vesicle compositions

Publications (2)

Publication Number Publication Date
JP2022549328A JP2022549328A (ja) 2022-11-24
JP2022549328A5 true JP2022549328A5 (enExample) 2024-12-06

Family

ID=72840646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022518957A Pending JP2022549328A (ja) 2019-09-25 2020-09-25 細胞外小胞組成物

Country Status (11)

Country Link
US (1) US20240099973A1 (enExample)
EP (1) EP4034081A1 (enExample)
JP (1) JP2022549328A (enExample)
KR (1) KR20220092654A (enExample)
CN (1) CN114727947A (enExample)
AU (1) AU2020355240A1 (enExample)
BR (1) BR112022005614A2 (enExample)
CA (1) CA3152478A1 (enExample)
IL (1) IL291690A (enExample)
MX (1) MX2022003570A (enExample)
WO (1) WO2021062317A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4196144A1 (en) 2020-08-17 2023-06-21 Codiak BioSciences, Inc. Methods of treating cancer
US11931458B2 (en) 2021-01-11 2024-03-19 Babak Ghalili Exosome systems, products and methods
KR20230166101A (ko) * 2021-04-01 2023-12-06 론자 세일즈 아게 세포외 소포 조성물
AR128774A1 (es) * 2022-03-18 2024-06-12 Merck Patent Gmbh Métodos y composiciones para purificar pequeñas vesículas extracelulares
WO2023195976A1 (en) * 2022-04-05 2023-10-12 Babak Ghalili Exosome systems, products and methods
US20250382613A1 (en) * 2022-06-30 2025-12-18 Lonza Sales Ag Methods of using extracellular vesicle-aso targeting stat6
CN115282065B (zh) * 2022-08-11 2024-03-15 顾帅 一种含间充质干细胞外泌体的冻干粉及其制备方法和应用
JP7730003B2 (ja) * 2023-02-10 2025-08-27 中国▲医▼薬大学 細胞外小胞/エクソソーム保存溶液及びその混合溶液
WO2024206778A1 (en) * 2023-03-30 2024-10-03 Exoone Bio. Co., Ltd. Radiolabeled exosome and method and kit for preparing same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2456964T3 (es) 2007-02-07 2014-04-24 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
WO2009088401A2 (en) 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Immunostimulatory combinations of tlr ligands and methods of use
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ, インコーポレイテッド Toll様受容体アゴニスト処方物およびその使用
CA2777198C (en) 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
MX2012004247A (es) * 2009-10-06 2012-06-25 Angiochem Inc Composiciones y metodos para el transporte de agentes terapeuticos.
CN107970451A (zh) 2010-10-01 2018-05-01 帆德制药股份有限公司 Tlr激动剂和联合治疗的治疗应用
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
ES2982836T3 (es) 2013-04-29 2024-10-17 Memorial Sloan Kettering Cancer Center Composiciones y métodos para alterar la señalización de segundos mensajeros
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
ME03586B (me) 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
WO2015185565A1 (en) 2014-06-04 2015-12-10 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
US20170340658A1 (en) 2014-12-16 2017-11-30 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
ES2764178T3 (es) 2014-12-16 2020-06-02 Kayla Therapeutics Dinucleótidos cíclicos fluorados para inducción de citocinas
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
UY36969A (es) 2015-10-28 2017-05-31 Novartis Ag Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon
SG11201804117XA (en) * 2015-11-18 2018-06-28 Univ Georgia Neural cell extracellular vessicles
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
WO2018070939A1 (en) * 2016-10-12 2018-04-19 Agency For Science, Technology And Research Method for lyophilising an exosome
AU2017368050A1 (en) * 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
PT3512861T (pt) 2016-12-01 2021-04-29 Takeda Pharmaceuticals Co Dinucleotídeos cíclicos
MX2020001790A (es) * 2017-08-25 2020-07-22 Codiak Biosciences Inc Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana.
US20190175506A1 (en) * 2017-11-17 2019-06-13 Codiak Biosciences, Inc. Loading of Extracellular Vesicles through Imparting of Mechanical Shear
WO2019099942A1 (en) 2017-11-17 2019-05-23 Codiak Biosciences, Inc. Compositions of engineered exosomes and methods of loading luminal exosomes payloads
KR20200108275A (ko) * 2017-12-28 2020-09-17 코디악 바이오사이언시즈, 인크. 면역-종양학 및 항-염증 요법을 위한 엑소좀
GB201802163D0 (en) * 2018-02-09 2018-03-28 Evox Therapeutics Ltd Compositions for EV storage and formulation
AU2019218991A1 (en) * 2018-02-12 2020-07-09 Lonza Sales Ag Methods and compositions for macrophage polarization
WO2019183578A1 (en) * 2018-03-23 2019-09-26 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist
CN113286603B (zh) 2018-11-16 2025-07-22 隆萨销售股份公司 工程化的细胞外囊泡及其用途
US12233356B2 (en) * 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles

Similar Documents

Publication Publication Date Title
EP1197221B1 (en) G-csf preparations stabilized over long time
EP0909564B1 (en) Erythropoietin solution preparation stabilized with amino acids
JP4683810B2 (ja) 長期安定化製剤
ES2706296T3 (es) Formulaciones de Factor VIII
ES2393180T3 (es) Preparados de insulina libre de cinc o con bajo contenido en cinc con estabilidad mejorada
JPWO2001064241A1 (ja) 長期安定化製剤
JP2013511522A (ja) ダプトマイシン製剤
CN1264569C (zh) 无蛋白制剂
JP2636499B2 (ja) プラスミノーゲン活性化因子蛋白の薬学的組成物
JP5774561B2 (ja) 安定なボルテゾミブ製剤
CN1449292A (zh) 长期稳定溶液制剂
US8119595B2 (en) Stable, aqueous solution of human erythropoietin, not containing serum albumin
KR20240136382A (ko) Igf-1/igfbp의 산화를 감소시키기 위한 조성물 및 방법
US10682326B1 (en) Stable melphalan liquid injectable formulations
JP4454571B2 (ja) 蛋白非添加製剤
JPWO2002017957A1 (ja) 長期安定化溶液製剤
HK1036224B (en) Protein-free preparations
KR20080029020A (ko) 저장 안정성 에리스로포이에틴 조성물
HK1106705B (en) Novel albumin-free factor viii formulations